NCT00749788

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects With Low HDL-C Levels

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Akros Pharma Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	JTT-302	JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
DRUG	JTT-302	JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
DRUG	Placebo	Matching placebo tablets, oral, 30 minutes after the start of the morning meal

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2008-09-09
• Last updated: 2013-02-04

Locations

1 site across 1 country: United States